SCHEMBL4322362

SCHEMBL4322362

c1ccc(-c2cc(-c3cnccn3)no2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.61
NPC1 O15118 7/20 0.61
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
CYP1A2 P05177 3/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP3A4 P08684 1/20 0.49
PIM1 P11309 1/20 0.47
SMN1; SMN2 Q16637 4/20 0.46
PTGS2 P35354 2/20 0.46
CXCR1 P25024 2/20 0.45
HPGDS O60760 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HPGD P15428 2/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319862 0.89 CYP2C9 (0.52) RAB9ANPC1CYP1A2CYP2C9CYP2C19
SCHEMBL4325938 0.84 CYP3A4 (0.51) RAB9ANPC1CASP3SENP8SENP7
SCHEMBL4315720 0.84 MAPT (0.50) RAB9ANPC1CYP1A2PIM1SMN1; SMN2
SCHEMBL4315678 0.84 CYP1A2 (0.54) RAB9ANPC1CYP1A2CYP2C9CYP2C19
SCHEMBL7448259 0.81 RAB9A (0.67) RAB9ANPC1CASP3SENP8SENP7
SCHEMBL4315843 0.81 CYP3A4 (0.54) RAB9ANPC1CYP1A2CYP2C9CYP2C19
SCHEMBL4319494 0.81 CYP3A4 (0.56) CYP1A2CYP2C9CYP2C19CYP3A4ALDH1A1
SCHEMBL4322525 0.80 RAB9A (0.70) RAB9ANPC1CASP3SENP8SENP7
SCHEMBL4321646 0.80 FYN (0.48) RAB9ANPC1SMN1; SMN2ALDH1A1MEN1
SCHEMBL4318598 0.79 CHRNB2 (0.43) RAB9ANPC1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO claimed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US claimed
US-8383658-B2 Isoxazole based neuronal nicotinic receptor ligands and methods of use ABBOTT LABORATORIES (US) 2013-02-26 US disclosed
WO-2009149135-A1 BIS (HETERO ) ARYL SUBSTITUTED ISOXAZOLES FOR USE AS NEURONAL NICOTINIC RECEPTOR MODULATORS ABBOTT LABORATORIES (US) 2009-12-10 WO disclosed
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof ABBOTT LABORATORIES (US) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306096-A1 Novel Isoxazoles and Methods of Use Thereof XDH, PRDX5, CYP4X1 RAB9A 4160/4885NPC1 837/4885CASP3 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.